Investigational drug · Phase 2
ML-007C-MA
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psychosis Associated With Alzheimer's Disease, Schizophrenia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
4
Any phase or sponsor naming "ML-007C-MA"
First trial start
2025
Jun 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ML-007C-MA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psychosis Associated With Alzheimer's Disease
- Schizophrenia
Approved drugs for the same conditions: Alzheimer's disease · Schizophrenia · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ML-007C-MA" as an intervention, largest first.
MapLight TherapeuticsIndustry
NCT07459647 · 500 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 2030
Drug: ML-007C-MA · For: Schizophrenia
Sites: Little Rock, Arkansas; Rogers, Arkansas; Bellflower, California · 45 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaPivotal-lookingCompleted
MapLight TherapeuticsIndustry
NCT07038876 · 307 participants · Start Jun 27, 2025 · Primary completion Jun 4, 2026
Drug: Placebo; ML-007C-MA BID and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Bellflower, California; Culver City, California · 24 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPivotal-lookingRecruiting
MapLight TherapeuticsIndustry
NCT06887192 · 300 participants (planned) · Start Aug 15, 2025 · Primary completion Dec 2027
Drug: ML-007C-MA; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 69 sites in all
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitation
MapLight TherapeuticsIndustry
NCT07459660 · 210 participants (planned) · Start Mar 25, 2026 · Primary completion Mar 2029
Drug: ML-007C-MA · For: Psychosis Associated With Alzheimer's Disease
Sites: Anaheim, California; Denver, Colorado; Doral, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.